VTYX (Ventyx Biosciences) 12-1 Month Momentum % : -0.46% (As of Dec. 12, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ventyx Biosciences 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-12), Ventyx Biosciences's 12-1 Month Momentum % is -0.46%.

The industry rank for Ventyx Biosciences's 12-1 Month Momentum % or its related term are showing as below:

VTYX's 12-1 Month Momentum % is ranked better than
59.68% of 1441 companies
in the Biotechnology industry
Industry Median: -13.28 vs VTYX: -0.46

Competitive Comparison of Ventyx Biosciences's 12-1 Month Momentum %

For the Biotechnology subindustry, Ventyx Biosciences's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ventyx Biosciences's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ventyx Biosciences's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Ventyx Biosciences's 12-1 Month Momentum % falls into.

Ventyx Biosciences (NAS:VTYX) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ventyx Biosciences (NAS:VTYX) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Ventyx Biosciences 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Ventyx Biosciences's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ventyx Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ventyx Biosciences Inc (NAS:VTYX) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

12790 El Camino Real, Suite 200, San Diego, CA, USA, 92130

Website

https://www.ventyxbio.com

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Executives

Raju Mohan	director, officer: Chief Executive Officer	C/O VENTYX BIOSCINECES, INC., 332 ENCINITAS BLVD., SUITE 200, ENCINITAS CA 92024
Martin Auster	officer: Chief Financial Officer	C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024
John Nuss	officer: Chief Scientific Officer	C/O VENTYX BIOSCIENCES, INC., 332 ENCINITAS BLVD. SUITE 200, ENCINITAS CA 92024
Christopher W Krueger	officer: Chief Business Officer	C/O ARDEA BIOSCIENCES INC, 2131 PALOMAR AIRPORT ROAD SUITE 300, CARLSBAD CA 92011
Nsv Partners Iii Lp	10 percent owner	500 WEST PUTNAM AVE, SUITE 400, GREENWICH CT 06830
Somu Subramaniam	director, 10 percent owner	C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
William J. Sandborn	officer: See Remarks	C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024
Sheila Gujrathi	director	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
William Richard White	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Onaiza Cadoret-manier	director	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Allison Hulme	director	C/O SOPHIRIS BIO INC., 1258 PROSPECT ST, LA JOLLA CA 92037
Venbio Global Strategic Fund Iii, L.p.	10 percent owner, other: See Remarks	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston	director, 10 percent owner	200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116